Zachary Nahmias, MD
Dermatology · Jonesboro, ARNPI 1093129397
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Sanofi at 50.2% of the total. Reporting peaked in 2024 at $9,615 and has fallen 70.8% since, to $2,803 in 2025. Among dermatology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $42.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- AbbVie$1K
- Lilly USA, LLC$1K
- Sun Pharmaceutical Industries Inc.$897
- Johnson & Johnson$822
- LEO Pharma Inc.$686
- plus $3K from 24 others
Across 5 payments — averaging $2110.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acrotech Biopharma Inc.$11K
What the payments were for
- Consulting fees$6,24542%
- Travel & lodging$8466%
- Food & beverage$7,29549%
- Education$5484%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $7,499 |
| AbbVie | 58 | $1,114 |
| Lilly USA, LLC | 66 | $1,007 |
| Sun Pharmaceutical Industries Inc. | 34 | $897 |
| Johnson & Johnson | 33 | $822 |
| LEO Pharma Inc. | 27 | $686 |
| Tersera Therapeutics LLC | 1 | $393 |
| Regeneron Healthcare Solutions, Inc. | 12 | $299 |
| Incyte Corporation | 17 | $298 |
| Biowound Solutions, Inc. | 8 | $266 |
| E.r. Squibb & Sons, L.L.C. | 11 | $224 |
| Springworks Therapeutics, Inc. | 6 | $180 |
| Novartis | 8 | $151 |
| UCB, Inc. | 8 | $150 |
| Reprise Biomedical, Inc. | 4 | $143 |
| Janssen Scientific Affairs, LLC | 2 | $120 |
| Pfizer | 5 | $90 |
| Organon | 8 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Galderma Laboratories, L.p. | 4 | $74 |
| Organogenesis Inc. | 3 | $71 |
| Boehringer Ingelheim | 4 | $65 |
| Arcutis Biotherapeutics, Inc. | 1 | $49 |
| Dermavant Sciences, Inc. | 3 | $49 |
| Genentech USA, Inc. | 2 | $42 |
| Biofrontera Inc. | 1 | $22 |
| Amgen | 1 | $16 |
| Aroa Biosurgery Incorporated | 1 | $14 |
| Prugen, Inc. Pharmaceuticals | 1 | $13 |
| Integra Lifesciences Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,935 in reported general payments places this provider in the 90th percentile of 75 dermatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 70 | $292,121 |
| RinvoqUpadacitinib | 15 | $96,962 |
| OpzeluraRuxolitinib Phosphate | 35 | $88,542 |
| Clobetasol Propionate | 130 | $4,752 |
| Clindamycin Phosphate | 38 | $1,282 |
| Tretinoin | 14 | $1,191 |
| Doxycycline Hyclate | 54 | $1,089 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $878 |
| Ketoconazole | 49 | $717 |
| ValacyclovirValacyclovir Hcl | 31 | $496 |
| Doxycycline Monohydrate | 18 | $489 |
| CiclopiroxCiclopirox Olamine | 16 | $454 |
| Minocycline Hcl | 15 | $315 |
| MethotrexateMethotrexate Sodium | 24 | $282 |
| Triamcinolone Acetonide | 29 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,114 | $96,96215 claims |
| Incyte CorporationOpzelura | $298 | $88,54235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 dermatology providers in Arkansas.
Other dermatology in Jonesboro
- Adam SillsJonesboro$9K
- Mallory HurstJonesboro$5K
- Sandra JohnsonFort Smith$543K
- Scott JacksonFayetteville$533K
- Mildred CliftonBentonville$92K
- Lance HenryFayetteville$39K
- Jennifer JacksPine Bluff$21K
- Phillip StitesFort Smith$15K
- Brian WayneLittle Rock$13K
- Andrea MabryLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.